ClinicalTrials.gg
TerminatedNCT01033019Updated Oct 30, 2015Results posted

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

A Phase 2 interventional study of LDE225 0.75% and Vehicle in Sporadic Superficial and Nodular Skin Basal Cell Carcinomas, sponsored by Novartis Pharmaceuticals. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-10-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
The data from participants with sBCCs showed insufficient efficacy with current formulation and treatment conditions.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Carcinoma, Basal Cell with a site in Australia — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Basal Cell · Australia.

Enrollment
14th of 17
25 · median 75
Started
2009
with 1 other
Phase 2
10 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
2 of 18
Novartis Pharmaceuticals

Among the 18 studies in Carcinoma, Basal Cell with a site in Australia, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2009, is one of 10 in phase 2, and was the 7th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

1 of the 18 studies in Carcinoma, Basal Cell with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Basal Cell with a site in Australia, or all of them as a file.
02

Study summary

This was a double-blinded, randomized, vehicle-controlled study in sporadic superficial BCC (sBCC) and nodular BCC (nBCC) patients which consisted of a 21-day screening period, a treatment period of 6 weeks (topical 0.75% LDE225 cream application b.i.d) ending with post treatment biopsies, as safety visit one week after final study drug administration (Day 50), a visit on Day 83 for excision of the treated BCC, and an end of study evaluation (Day 90).

03

Conditions studied

  • Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Browse trials for

Keywords

  • Basal cell carcinomas,
  • sporadic,
  • superficial and nodular,
  • skin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with one confirmed superficial and nodular basal cell carcinoma (8-20 mm) eligible for surgical excision on selected body areas (scalp, arm, frontal trunk, posterior trunk, upper legs)

Exclusion criteria

Exclusion Criteria:

  • Previous treatment of the sBCC that are selected for treatment.
  • Any systemic treatment which is known to affect BCCs esp. cytostatic treatments, retinoids and photodynamic treatments.
  • Dark-skinned persons whose skin color prevents readily assessment of skin reactions

Other protocol defined Incl./Excl. criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    LDE225 0.75%

    Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.

    Drug: LDE225 0.75%

  • Placebo comparator
    Vehicle

    Participants topically applied matching placebo cream twice daily for 6 weeks.

    Drug: Vehicle

Interventions

  • 0.75% cream

  • DrugVehicle

    matching placebo cream to 0.75% LDE225 cream

06

What researchers measure

Primary outcomes

  1. Clinical Evaluation of sBCCs Tumors

    The clinical response parameters were defined as (i) complete response (i.e., there is no longer any visible evidence of a lesion consistent with BCC at this site), (ii) partial response (i.e., although a BCC still remains at this site, it has demonstrated a visible decrease in size compared with baseline), and (iii) no response / worsening (i.e., the BCC has not demonstrated any visible decrease in size compared with baseline).

    Time frame: Day 43

07

Results

Posted Oct 30, 2015

Participant flow

Twenty-five participants were enrolled into the trial. However, one participant was excluded from the efficacy analysis. Therefore, the enrollment number differs from the number started below.

Participant flow — Overall Study
MilestoneLDE225 0.75%Vehicle
Started168
Completed158
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryClinical Evaluation of sBCCs Tumors

The clinical response parameters were defined as (i) complete response (i.e., there is no longer any visible evidence of a lesion consistent with BCC at this site), (ii) partial response (i.e., although a BCC still remains at this site, it has demonstrated a visible decrease in size compared with baseline), and (iii) no response / worsening (i.e., the BCC has not demonstrated any visible decrease in size compared with baseline).

Time frame:
Day 43
Reported as:
Number · Participants
Clinical Evaluation of sBCCs Tumors
ParticipantsLDE225 0.75%Vehicle
Complete response31
Partial response94
No response43

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225 0.75% - sBCC—0/16 (0%)8/16 (50%)
Vehicle - sBCC—0/8 (0%)5/8 (62.5%)
LDE225 0.75% - nBCC—0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventLDE225 0.75% - sBCCVehicle - sBCCLDE225 0.75% - nBCC
DiarrhoeaGastrointestinal disorders0/160/81/1
Body temperature increasedInvestigations0/160/81/1
HeadacheNervous system disorders0/161/81/1
Application site dermatitisGeneral disorders0/161/80/1
Application site pruritusGeneral disorders0/161/80/1
Acute tonsillitisInfections and infestations0/161/80/1
Gastrointestinal infectionInfections and infestations2/160/80/1
Oral herpesInfections and infestations0/161/80/1
Blood creatinine increasedInvestigations0/161/80/1
Blood glucose increasedInvestigations0/161/80/1

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LDE225 0.75%VehicleTotal
Mean63 ± 7.363 ± 7.563 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)LDE225 0.75%VehicleTotal
Female448
Male12416
08

Study locations

4 sites
  • Novartis Investigative Site
    Benowa, Queensland 4217, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2009
First posted
Dec 16, 2009
Start
Dec 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Oct 30, 2015
Last update
Oct 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01033019
Responsible party
Sponsor
First posted
Dec 16, 2009
Start date
Dec 2009
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Oct 30, 2015
Last update
Oct 30, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion